Small Molecule Development & Manufacturting at Quotient Sciences

Live Webinar: CMC and Clinical Strategies for the Successful Development of Injectable and Oral Peptide Drugs

6 February 2025
Overview

Join us for an enlightening session on the latest developments in oral peptides with our Chief Scientific Officer, Dr. Andrew Lewis.

Our next webinar will explore critical drivers and innovative delivery options for peptide drugs. Hear about these topics and more from our speaker:

  • The clinical development strategies to switch delivery routes from intravenous to subcutaneous administration
  • Strategies to phase CMC investment to reduce risk and meet the the target product profile (TPP) of your drug
  • The role of rapid clinical pharmacokinetic prototyping to optimize peptide product development

Dr. Lewis will highlight CMC and clinical learnings from over 14 oral peptide programs evaluating 10 different permeation enhancers that Quotient Sciences has worked on over the past decade, with insights from the use of PBPK modelling to inform oral peptide development.

Don't miss out on this presentation! 

 

In partnership with: 

Times

February 6th, 2025

8:00am PST, 11:00am EST, 4:00pm GMT

Here's what you'll learn

Join us for our upcoming webinar to hear about:

Join us for our next webinar
 

Clinical development strategies to switch delivery routes from IV to SC

Join us for our next webinar
 

How to phase CMC investment to reduce risk and reach TPP

Join us for our next webinar
 

How PBPK modelling can inform oral peptide development

Join us for our next webinar
 

Using rapid clinical pharmacokinetic prototyping to optimize product development

Meet our speaker:

Dr. Andrew Lewis

Chief Scientific Officer

Dr. Andrew (Andy) Lewis is the Chief Scientific Officer at Quotient Sciences. As the leader of Quotient Sciences' scientific teams...

About Andrew

More insight from our experts:

Read More
Modified Release, Dr. Helen Baker, FreeThink ASAPprime Obtaining rapid stability data through ASAPprime®: Q&A with Helen Baker By: Dr. Helen Baker
Read More
Translational Pharmaceutics, Clinical Pharmacology, Peptides, Modified Release, Formulation Development, Dr. Andrew Lewis, Dr. Stuart Mair Exploring GLP-1 Agonists: How they work and what the future holds for this promising treatment By: Dr. Andrew Lewis
Read More